Abstract: This invention relates to methods for promoting reinnervation of auditory hair cells, specifically, by inhibiting Repulsive Guidance Molecule a (RGMa), a repulsive axonal guidance molecule that is expressed in the cochlea, or its receptor, neogenin.

Abstract: Provided herein are methods of treating HPV-negative tumors comprising administering an effective amount of an antagonist of the PDL-1/PD-1 interaction (e.g., an anti-PDL-1 or anti-PD-1 antibody antigen binding fragment thereof).

Abstract: The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases.

Abstract: Humanized antibodies and antibody fragments thereof that bind to ?v?6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent ?v?6-mediated diseases such as fibrosis and cancer.

Abstract: This disclosure is in the field of anti-Activin receptor IIB (ActRIIB) antibodies. In particular, it relates to the use of said antibodies for treating muscle disorders, such as muscle wasting due to disease or disuse.

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.

Abstract: The present invention relates to novel isolated antibodies, or the derivatives or antigen binding fragments of same, capable of binding to CXCR4 but also of inducing conformational changed of the CXCR4 homodimers and able to inhibit HIV-1 primary isolate replication in PBMC. More particularly, the present invention relates to the 515H7 and 301aE5 monoclonal antibodies, specific to the CXCR4 protein, as well as their use for the treatment of HIV infection. Pharmaceutical compositions comprising such antibodies and a process for the selection of such antibodies are also covered.

Abstract: The present disclosure provides antibodies and antigen binding fragments thereof that bind to an epitope within an interleukin-3 receptor ?.

Abstract: The present invention provides compositions and methods relating to antigen binding proteins against CCR7, including antibodies, nucleic acids, vectors, methods of making the antigen binding proteins, and methods of using the antigen binding proteins.

Abstract: The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.

Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Abstract: The present invention provides anti-RANKL monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.

Abstract: The present invention is directed to a monoclonal antibody that recognizes human CD9 in its native form. The invention is also directed to a hybridoma cell line that produces the monoclonal antibody, and exosome isolation kits using the antibody.

Abstract: Disclosed are methods and compositions of anti-B cell antibodies, preferably anti-CD22 antibodies, for diagnosis, prognosis and therapy of B-cell associated diseases, such as B-cell malignancies, autoimmune disease and immune dysfunction disease. In certain embodiments, trogocytosis induced by anti-B cell antibodies may determine antibody efficacy, disease responsiveness and prognosis of therapeutic intervention. In other embodiments, optimal dosages of therapeutic antibody may be selected by monitoring the degree of trogocytosis induced by anti-B cell antibodies.

Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.

Abstract: The present invention relates to methods and pharmaceutical compositions for treating breast cancers. In particular, the present invention relates to a method for predicting the survival of a patient suffering from a breast cancer comprising i) determining the expression level of Vangl2 in a tumor sample obtained from the patient, ii) comparing the expression level determined at step i) with a predetermined reference value and iii) providing a poor prognosis when the expression level determined at step i) is higher than the predetermined reference value. The present invention also relates to a method for treating a patient suffering from a breast cancer comprising the steps consisting of i) predicting the survival of the patient according to claim 1 and ii) administering the patient with an anti-Vangl2 antibody or an inhibitor of Vangl2 expression or an inhibitor of the Vangl2-p62 interaction when it is concluded that the patient has a poor prognosis at step i).

Abstract: The present disclosure provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer, pancreatic cancer and skin cancer treatment, and for drug development.

Abstract: Human antibody fragments against chrondroitin sulfate proteoglycan 4 can be used to deliver cytotoxic agents to cells which express CSPG4. The agents can be diagnostic or therapeutic moieties. They may be linked by covalent or non-covalent linkages to the antibody fragments. They may be produced as a genetic fusion product or joined together synthetically, for example. When the human antibody fragments are internalized by the cells to which they bind, they can carry with them the attached agents. Thus toxic agents having intracellular targets have enhanced killing upon internalization.

Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.

Abstract: In this application are described high affinity anti-GD2 antibody agents, and various methods and reagents related thereto, including for example for the detection, prevention, and/or therapeutical treatment of GD2-related diseases, in particular, neuroblastoma.

Abstract: The present invention is aimed to provide a method for preparing an acceptor that is N-glycan hydrolyzed antibody or a Fc fragment thereof used for producing antibody having a homogeneous N-glycan structure; a method for determining a combination of endoglycosidases for use in said preparation; and a method for measuring N-glycans linked to an antibody. The present invention is directed to a method for producing a N-glycan hydrolyzed antibody or Fc fragment thereof, comprising reacting the antibody or the Fc fragment thereof with several endoglycosidases; and a method for determining quantitative information of an objective N-glycan with a desired structure linked to an antibody or a Fc thereof, comprising a protease treatment step and a glycopeptide measurement step, etc.

Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.

Abstract: The application discloses a combination of two monospecific TFPI antibodies, wherein one antibody is capable of specifically binding TFPI (1-181) and the other antibody is capable of specifically binding TFPI (182-276), as well as bispecific anti-TFPI antibodies derived from two such monospecific antibodies. Both the combination of the two monospecific antibodies and the bispecific antibody strongly enhance thrombin generation by neutralising full length TFPI?, even where the concentration of TFPI is abnormally elevated.

Abstract: This invention relates to RON compositions, in particular RON composition comprising a RON agonist, and methods of using the compositions for the treatment of diseases. The invention also relates to diagnosis of RON-associated or MSP-associated diseases.

Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inhibiting PCSK9 binding to LDLR and having increased pH sensitivity, improved binding affinity and/or increased in vivos half life. In embodiments, the antigen binding proteins specifically bind PCSK9 and have increased pH sensitivity, improved binding affinity and/or increased in vivos half life.

Abstract: The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.

Abstract: Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (GAD65) that is bound by antibody b96.11, and anti-idiotypic antibodies that are capable of competing with GAD65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of Type 1 diabetes and for inhibiting insulitis and other diabetic symptoms. Also provided are methods for detecting a susceptibility to Type 1 diabetes in a subject and for detecting the presence of anti-idiotypic antibodies to GAD65. The method comprises contacting a specimen with an antibody of the invention. The method further comprises detecting binding of the molecule to the specimen. The absence (or relative absence) of binding is indicative of susceptibility to Type 1 diabetes and of the absence of anti-idiotypic antibodies.

Abstract: The present disclosure relates to anti-IgE antibodies that bind to novel antigenic epitopes of the CsmX domain, e.g., SVPHPRCHCGAGRA (SEQ ID NO: 4) and the uses thereof in treating IgE-mediated diseases.

Abstract: The present invention concerns the use of immunoglobulins of IgG1 type, and more generally of ligands of the CD32 receptor, for the treatment of inflammatory diseases and manifestations, in particular of allergies and auto-immune diseases, more particularly the treatment of allergic asthma, the immunoglobulins and ligands being administered via mucosal route, in particular via sublingual route.

Abstract: The present invention provides to a bispecific antibody construct comprising a first human binding domain which binds to human CDH19 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Abstract: A cellulose acetate according to the present invention has a total degree of acetyl substitution of 0.4 to 1.1 and has a compositional distribution index (CDI) of 3.0 or less, where the CDI is specified by the formula: CDI=(Measured value of half height width of chemical composition)/(Theoretical value of half height width of chemical composition) where the measured value of half height width of chemical composition is a half height width of chemical composition determined by analyzing a cellulose acetate propionate by HPLC, where the cellulose acetate propionate is prepared by propionylating all residual hydroxy groups of the cellulose acetate (sample); and Theoretical value of half height width of chemical composition=2·35482?{square root over (3*DPw*(DS/3)*(1?DS/3))}{square root over (3*DPw*(DS/3)*(1?DS/3))}/DPw??[Math.

Abstract: A method of producing regenerated cellulose and hemicellulose from a fibre pulp which is prepared by using chemical cooking. Hemicellulose and, correspondingly, cellulose is separated from the pulp, in order to form separate fractions, by dissolving them in such a solvent or an aqueous solution of it, from which they are precipitated by adding water, after which the regenerated hemicellulose and cellulose can be recovered. Hemicellulose-containing pulp, which for example is used as raw material of paper, can be efficiently fractionated into polymeric hemicellulose-rich fractions and very pure cellulose fractions, such as regenerated cellulose fibre, various cellulose particles or cellulose films.

Abstract: The present invention relates to a process for preparing polydextrose by using a microdevice. It further relates to the use of a microdevice for the polycondesation reactions.

Abstract: In a continuous emulsion polymerization process, at least one monomer, an aqueous phase, and at least two different redox initiators are added to a continuous polymerization reactor comprising a first zone and a second zone. At least one redox initiator is added to the first zone and at least one redox initiator is added to the second zone.

Abstract: The present invention discloses an active metallocene catalyst system prepared with a hafnium-based metallocene catalyst system and an activating agent comprising an aluminoxane and a sterically hindered Lewis base.

Abstract: Catalyst systems and methods for making and using the same. A catalyst system can include a non-metallocene catalyst having the structure: wherein M is a group 4 element, each of R13-R20 are independently a hydrogen or a methyl group, wherein at least one of R13-R20 is a methyl group, Ar is an aryl group or a substituted aryl group, Ar? is an aryl group or a substituted aryl group, and each X is, independently, a hydride group, an amide, a benzyl group, a methyl group, a chloro group, a fluoro group, or a hydrocarbyl group.

Abstract: A solid catalyst component for the (co)polymerization of olefins CH2?CHR, in which R is a hydrocarbyl radical with 1-12 carbon atoms, optionally in mixture with ethylene, comprising Ti, Mg, Cu, Cl, and an electron donor compound characterized by the fact that the Cu/Ti weight ratio is lower than 0.5.

Abstract: A bimodal polyethylene copolymer comprising a lower molecular weight (LMW) component and a higher molecular weight (HMW) component, the copolymer having a z-average molecular weight (MZ) of from about 1,000 kg/mol to about 2,500 kg/mol, a weight fraction of the LMW component (LMW fr.) of from about 0.60 to 0.85, a ratio of a weight average molecular weight (MW) of the HMW component (HMW MW) to a MW of the LMW component (LMW MW) of from about 14 to about 25, a zero shear viscosity (?0) of from about 5×105 Pa-s to about 1×107 Pa-s and a HMW MW of from about 800 kg/mol to about 1,500 kg/mol.

Abstract: A method of forming a polyelectrolyte polymer by photopolymerizing a monomer having an ionic group covalently linked to a photocurable group. The ionic group can be borate and/or phosphonium ion. The polymer can be cross-linked as by diacrylate.

Abstract: The method includes providing a high impact polystyrene (HIPS) reaction system, wherein the HIPS reaction system has a devolitalizer downstream of a reactor and injecting a retarding agent into the HIPS reaction system prior to the devolitalizer.

Abstract: A method for preparing a functionalized polymer, the method comprising the steps of: (i) polymerizing monomer with a coordination catalyst to form a reactive polymer; and (ii) reacting the reactive polymer with a nitroso compound.

Abstract: The present disclosure provides a process. In an embodiment, the process includes producing a propylene-based polymer in a gas-phase polymerization reactor (10) under polymerization conditions. The polymerization conditions include a combined propylene-plus-propane partial pressure from 290 psia to 450 psia. The process further includes maintaining the combined propylene-plus-propane partial pressure in the range from 290 psia to 450 psia while simultaneously: (i) reducing propylene partial pressure in the gas-phase polymerization reactor; (ii) adding propane to the gas-phase polymerization reactor; (iii) introducing at least one C4-C10 comonomer into the gas-phase polymerization reactor (26); and forming a propylene/C4-C10 interpolymer in the gas-phase polymerization reactor (44).

Abstract: Propylene terpolymers are prepared by polymerizing propylene, ethylene and an alpha-olefin selected from the group of C4-C8 alpha-olefins in the presence of a catalyst system obtained by contacting a solid catalyst component comprising a magnesium halide, a titanium compound having at least a Ti-halogen bond and at least two electron donor compounds one of which being present in an amount from 40 to 90% by mol with respect to the total amount of donors and selected from succinates and the other selected from 1,3 diethers, an aluminum hydrocarbyl compound, and optionally an external electron donor compound.

Abstract: Provided is a method for producing an ?-olefin polymer, comprising the step of polymerizing one or more kinds of ?-olefins each having 3 to 30 carbon atoms with a polymerization catalyst obtained by using: (A) a metallocene compound; (B) an ionic compound capable of reacting with the metallocene compound to transform the compound into a cation; (C) an organometallic compound; and (D) one or more kinds of compounds selected from the group consisting of (d-1) an alcohol, (d-2) a phenol, and (d-3) an ether compound, the catalyst having a ratio between the component (A) and the component (D) of from 10:1 to 1:100 in terms of a molar ratio, and having a ratio of the component (D) to the component (C) of less than 1 in terms of a molar ratio.

Abstract: Polyethylene films may include a polyethylene copolymer polymerized in the presence of a hafnium-based metallocene catalyst, wherein the polyethylene comprises a solubility distribution breadth index (SDBI) less than or equal to 23° C.; a melt index (12) less than 1.5; a flow index (121) of from about 16 to about 28; and a melt flow ratio (121/12) of from about 18 to about 23. The film has a cling value that is at least 60% of a cling value the film has at 48 hours after time zero, and wherein time zero is equal to less than 24 hours.

Abstract: An ethylene-based polymer comprising about 80.0 to 99.0 wt. % of polymer units derived from ethylene and about 1.0 to about 20.0 wt. % of polymer units derived from one or more C3 to C20 ?-olefin comonomers; the ethylene-based polymer having: a CDBI of 60% to 80%; a melt index, I2.16, of about 4.0 to about 12.0 g/10 min.; a high-load melt index, I21.6, of 80.0 to about 160.0 g/10 min.; a melt index ratio (I21.6/I2.16) of 9.0 to 40.0; and a density of from about 0.910 to about 0.930 g/cm3. Articles, such as films, particularly suitable for use in pre-stretch applications, produced from such polymers and methods of making such articles are also provided.

Abstract: Provided are a cured product (for example, a film), in which the balance between hydrophilicity and abrasion resistance is superior, decrease in hydrophilicity by water is minimal, and the weather resistance is also superior, as well as a polymer and a polymer composition that can yield such a cured product. A polymer of the invention is a specific copolymer (i) having a sulfonic acid-containing group, an epoxy group, and a specific alkoxysilyl group in a molecule.

Abstract: A copolymer contains a structure unit represented by Chemical formula 1 and a structure unit represented by Chemical formula 2, where R represents a hydrogen atom or a methyl group, X represents a hydrogen atom or a cation, L1 and L2 each, independently represent alkylene groups having 2 to 18 carbon atoms.

Abstract: Provided herein are polymeric ionic salt catalysts that are useful in the non-enzymatic saccharification processes. The catalysts described herein hydrolyze cellulosic materials to produce monosaccharides and/or disaccharides. Saccharification of lignocellulosic materials, such as biomass waste products of agriculture, forestry and waste treatment, are of great economic and environmental relevance. As part of biomass energy utilization, attempts have been made to obtain ethanol (bioethanol) by hydrolyzing cellulose or hemicellulose, which are major constituents of plants.